Denecimig
Phase 3
Novo NordiskDenecimig is one of 6 therapeutic programs targeting Haemophilia A. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Haemophilia a
#DrugCompanyPhaseTrials
1ALHEMO
Novo NordiskPhase 3
Efanesoctocog Alfa
SanofiPhase 3
Mim8
Novo NordiskPhase 3
Nuwiq
OctapharmaPhase 3
Denecimig
Novo NordiskPhase 3
NNC0442-0344 a
Novo NordiskPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Denecimig. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company